Targeting triple negative breast cancer: Is p53 the answer?

Cancer Treatment Reviews

Volumn 39, Issue 5, 2013, Pages 541-550

  Turner, Natalie ^a   Moretti, Erica ^a   Siclari, Olimpia ^a   Migliaccio, Ilenia ^a   Santarpia, Libero ^a   D'Incalci, Maurizio ^b   Piccolo, Stefano ^c   Veronesi, Andrea ^d   Zambelli, Alberto ^e   Del Sal, Gianni ^f,g   Di Leo, Angelo ^a  

^a HOSPITAL OF PRATO   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e IRCCS   (Italy)

^f Laboratorio Nazionale CIB LNCIB   (Italy)

^g UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 7 HYDROXYSTAUROSPORINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ARRY 438162; BUPARLISIB; CARBOPLATIN; CHECKPOINT KINASE 1; CISPLATIN; DINACICLIB; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GANETESPIB; GEMCITABINE; IRINOTECAN; LAPATINIB; LUMINESPIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PANOBINOSTAT; PICTILISIB; PROTEIN P53; ROSCOVITINE; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; UNINDEXED DRUG; VORINOSTAT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; CELL DIVISION; CHEMOSENSITIVITY; DNA DAMAGE; DNA REPAIR; HUMAN; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER;

EID: 84876976694     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.12.001     Document Type: Review

References (97)

1. Oakman C., Viale G., Di Leo A. Management of triple negative breast cancer. Breast 2010, 19:312-321.
2. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
3. O'Shaughnessy J., Osborne C., Pippen J.E., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, 364:205-214.
4. Gelmon K.A., Tischkowitz M., Mackay H., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12:852-861.
5. Carey L.A., Rugo H.S., Marcom P.K., et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012, 30:2615-2623.
6. Dumay A., Feugeas J.P., Wittmer E., et al. Distinct TP53 mutants in breast cancers subgroups. Int J Cancer 2013, 132(5):1227-1231. [Epub 2012 Sep 1].
7. Langerod A., Zhao H., Borgan O., et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007, 9:R30.
8. Shah S.P., Roth A., Goya R., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
9. Silver D.P., Richardson A.L., Eklund A.C., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28:1145-1153.
10. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
11. Ababneh M., Gotz C., Montenarh M. Downregulation of the cdc2/cyclin B protein kinase activity by binding of p53 to p34(cdc2). Biochem Biophys Res Commun 2001, 283:507-512.
12. Collavin L., Lunardi A., Del Sal G. P53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010, 17:901-911.
13. Dong Y., Hakimi M.A., Chen X., et al. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol Cell 2003, 12:1087-1099.
14. Luciani M.G., Hutchins J.R., Zheleva D., et al. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol 2000, 300:503-518.
15. Cully M., You H., Levine A.J., et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006, 6:184-192.
16. Walerych D., Napoli M., Collavin L., et al. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012, 33(11):2007-2017. [Epub 2012 Jul 20].
17. Girardini J.E., Napoli M., Piazza S., et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011, 20:79-91.
18. Braithwaite A.W., Del Sal G., Lu X. Some p53-binding proteins that can function as arbiters of life and death. Cell Death Differ 2006, 13:984-993.
19. Di Agostino S., Strano S., Emiliozzi V., et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006, 10:191-202.
20. Oren M., Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010, 2:a001107.
21. Goldstein I., Marcel V., Olivier M., et al. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 2011, 18:2-11.
22. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009, 9:701-713.
23. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594-604.
24. Adorno M., Cordenonsi M., Montagner M., et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137:87-98.
25. Bisso A., Collavin L., Del Sal G. P73 as a pharmaceutical target for cancer therapy. Curr Pharm Des 2011, 17:578-590.
26. Du Z., Li J., Wang L., et al. Overexpression of DeltaNp63alpha induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway. Cancer Sci 2010, 101:2417-2424.
27. Leong C.O., Vidnovic N., DeYoung M.P., et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007, 117:1370-1380.
28. Miller L.D., Smeds J., George J., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555.
29. Coutant C., Rouzier R., Qi Y., et al. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 2011, 17:2591-2601.
30. Troester M.A., Herschkowitz J.I., Oh D.S., et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006, 6:276.
31. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569.
32. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28:1075-1083.
33. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
34. Rosenbluth J.M., Mays D.J., Pino M.F., et al. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 2008, 28:5951-5964.
35. Wong S.W., Tiong K.H., Kong W.Y., et al. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 2011, 128:301-313.
36. Liu H., Zang C., Schefe J.H., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Anticancer Res 2011, 31:2713-2722.
37. Zeng Q., Yang Z., Gao Y.J., et al. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. Eur J Cancer 2010, 46:1132-1143.
38. Mayer I.A., Means-Powell J., Abramson V.G., et al. Phase II trial of RAD001 (everolimus), an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Cancer Res 2011, 71:151s. Abstr PD09-06.
39. Ma C.X., Cai S., Li S., et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 2012, 122:1541-1552.
40. Jones C.B., Clements M.K., Wasi S., et al. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest. Cancer Chemother Pharmacol 2000, 45:252-258.
41. Tse A.N., Rendahl K.G., Sheikh T., et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007, 13:591-602.
42. Carrassa L., Broggini M., Erba E., et al. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 2004, 3:1177-1181.
43. Flatten K., Dai N.T., Vroman B.T., et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 2005, 280:14349-14355.
44. Furuta T., Hayward R.L., Meng L.H., et al. P21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene 2006, 25:2839-2849.
45. Zenvirt S., Kravchenko-Balasha N., Levitzki A. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents. Oncogene 2010, 29:6149-6159.
46. Levesque A.A., Fanous A.A., Poh A., et al. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mol Cancer Ther 2008, 7:252-262.
47. Verlinden L. Vanden Bempt I, Eelen G, et al.: The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas. Cancer Res 2007, 67:6574-6581.
48. Edelman M.J., Bauer K.S., Wu S., et al. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res 2007, 13:2667-2674.
49. Jimeno A., Rudek M.A., Purcell T., et al. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 2008, 61:423-433.
50. Hotte S.J., Oza A., Winquist E.W., et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 2006, 17:334-340.
51. Lara P.N., Mack P.C., Synold T., et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 2005, 11:4444-4450.
52. Perez R.P., Lewis L.D., Beelen A.P., et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res 2006, 12:7079-7085.
53. Welch S., Hirte H.W., Carey M.S., et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 2007, 106:305-310.
54. Fracasso P.M., Williams K.J., Chen R.C., et al. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 2011, 67:1225-1237.
55. Ma C., Ellis M., Petroni G., et al. Clinical and correlative science results in a phase II study of UCN-01 in combination with irinotecan in triple negative breast cancer (TNBC). J Clin Oncol 2012, 30. Abstr 3047.
56. Zabludoff S.D., Deng C., Grondine M.R., et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008, 7:2955-2966.
57. Parsels L.A., Qian Y., Tanska D.M., et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 2011, 17:3706-3715.
58. Xu H., Cheung I.Y., Wei X.X., et al. Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G(1) checkpoint-defective neuroblastoma. Int J Cancer 2011, 129(8):1953-1962. [Epub 2011 Mar 8].
59. Sausville E., LoRusso P., Carducci M.A., et al. Phase I dose-escalation study of AZD7726 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. J Clin Oncol 2011, 29. Abstr 3058.
60. Ho A.L., Bendell J.C., Cleary J.M., et al. Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J Clin Oncol 2011, 29. Abstr 3033.
61. Daud A., Springett G., Mendelson D.S., et al. A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. J Clin Oncol 2010, 28. Abstr 3064.
62. Powers M.V., Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13(Suppl 1):S125-S135.
63. Muller P., Ceskova P., Vojtesek B. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J Biol Chem 2005, 280:6682-6691.
64. Peng Y., Chen L., Li C., et al. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 2001, 276:40583-40590.
65. Whitesell L., Sutphin P.D., Pulcini E.J., et al. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998, 18:1517-1524.
66. Hagn F., Lagleder S., Retzlaff M., et al. Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. Nat Struct Mol Biol 2011, 18:1086-1093.
67. Mehta P.P., Whalen P., Baxi S.M., et al. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. Clin Cancer Res 2011, 17:5432-5442.
68. Caldas-Lopes E., Cerchietti L., Ahn J.H., et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 2009, 106:8368-8373.
69. Friedland J.C., Sang J., Modi S., et al. Beyond HER2 and hormonal agents: the heat shock protein inhibitor ganetespib as a potential new breast cancer therapy. Cancer Res 2011, 71:416s. Abstr P3-17-05:416s.
70. Jhaveri K., Chandarlapaty S., Lake D., et al. A phase II trial of ganetespib: efficacy and safety in patients (pts) with metastatic breast cancer (MBC). Cancer Res 2011, 71. Abstr P1-17-08:242s-243s.
71. Lustberg M.B., Ramaswamy B. Epigenetic targeting in breast cancer: therapeutic impact and future direction. Drug News Perspect 2009, 22:369-381.
72. Kim T.Y., Bang Y.J., Robertson K.D. Histone deacetylase inhibitors for cancer therapy. Epigenetics 2006, 1:14-23.
73. Munster P.N., Troso-Sandoval T., Rosen N., et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001, 61:8492-8497.
74. Palmieri D., Lockman P.R., Thomas F.C., et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009, 15:6148-6157.
75. Li D., Marchenko N.D., Moll U.M. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011, 18:1904-1913.
76. Tate C.R., Rhodes L.V., Segar H.C., et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res 2012, 14:R79.
77. Ordentlich P., Tee L., Huynh Y., et al. Ex-vivo analysis of the isoform selective histone deacetylase inhibitor entinostat in triple-negative breast cancer tumors. J Clin Oncol 2009, 27. Abstr e14597.
78. Sabnis G.J., Goloubeva O., Chumsri S., et al. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 2011, 71:1893-1903.
79. Luu T.H., Morgan R.J., Leong L., et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008, 14:7138-7142.
80. Holm K., Hegardt C., Staaf J., et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010, 12:R36.
81. Elsheikh S.E., Green A.R., Rakha E.A., et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009, 69:3802-3809.
82. Sutherland R.L., Musgrove E.A. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res 2009, 11:112.
83. Johnson N., Cai D., Kennedy R.D., et al. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell 2009, 35:327-339.
84. Johnson N., Li Y.C., Walton Z.E., et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011, 17:875-882.
85. Jalal S., Earley J.N., Turchi J.J. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res 2011, 17:6973-6984.
86. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
87. Tutt A., Robson M., Garber J., et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced breast cancer. J Clin Oncol 2009, 27. Abstr CRA501:18s.
88. Parry D., Guzi T., Shanahan F., et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010, 9:2344-2353.
89. Mitchell C., Yacoub A., Hossein H., et al. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 2010, 10:903-917.
90. Appleyard M.V., O'Neill M.A., Murray K.E., et al. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 2009, 124:465-472.
91. Le Tourneau C., Faivre S., Laurence V., et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 2010, 46:3243-3250.
92. Mita M., Mita A., Moseley J., et al. A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3weeks in patients (pts) with advanced malignancies: final results. J Clin Oncol 2011, 29. Abstract 3080.
93. Binder B.R. A novel application for murine double minute 2 antagonists: the p53 tumor suppressor network also controls angiogenesis. Circ Res 2007, 100:13-14.
94. Araki S., Eitel J.A., Batuello C.N., et al. TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest 2010, 120:290-302.
95. Vassilev L.T., Vu B.T., Graves B., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
96. Shangary S., Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008, 14:5318-5324.
97. Villalonga-Planells R., Coll-Mulet L., Martinez-Soler F., et al. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 2011, 6:e18588.